Welcome to MS Views and News blog

MS Views and News, empowers those affected by Multiple Sclerosis (MS) with educational information, resources and services. Please scroll downward to find articles or videos of interest, then click to open the document or video.

Categories

Latest Blog Posts

October 22, 2011

Natalizumab (Tysabri)-Associated PML Survival Rates Exceed 80%

  • MS Research Study and Reports
    /
  • Multiple Sclerosis
    /
  • Tysabri
    /
AMSTERDAM—Early diagnosis through enhanced clinical vigilance and optimal management of progressive multifocal leukoencephalopathy (PML) may improve outcomes, according to data…
MS Research Study and Reports

October 22, 2011

Athersys has entered a partnership with a nonprofit multiple sclerosis group to investigate its adult stem cell technology for the treatment of MS

  • Multiple Sclerosis
    /
  • Stem Cell Related
    /
Fast Forward, a nonprofit subsidiary of the National Multiple Sclerosis Society, will commit up to $640,000 to fund animal studies…
Multiple Sclerosis

October 21, 2011

Optic Neuritis – The definition

  • Multiple Sclerosis
    /
  • Symptoms
    /
Definition Optic neuritis is a vision disorder characterized by inflammation of the optic nerve. Description Optic neuritis occurs when the…
Multiple Sclerosis

October 21, 2011

SURVEY FINDS MAJORITY OF PEOPLE WITH MULTIPLE SCLEROSIS REPORT DIFFICULTY WALKING OR MAINTAINING BALANCE

  • Alternative therapies and devices for Multiple Sclerosis (MS)
    /
  • Multiple Sclerosis
    /
Most people know that multiple sclerosis eventually leads to trouble walking. A new survey of more than 1,200 adults living…
Alternative therapies and devices for Multiple Sclerosis (MS)

October 21, 2011

The U.S. Food & Drug Administration (FDA) has accepted Sanofi’s new drug application (NDA) for oral teriflunomide as a potential therapy for people with relapsing forms of multiple sclerosis

  • MS Research Study and Reports
    /
  • Oral MS Medications
    /
Sanofi and its subsidiary, Genzyme, announced Thursday, October 20, that the U.S. Food & Drug Administration (FDA) has accepted Sanofi’s…
MS Research Study and Reports

October 21, 2011

About BG-12 – Possibly the Next Oral MS medication

  • MS Drug Therapies
    /
  • MS Research Study and Reports
    /
  • Oral MS Medications
    /
About BG-12 BG-12 (dimethyl fumarate) is an investigational oral therapy in late-stage clinical development for the treatment of RRMS, the…
MS Drug Therapies

October 21, 2011

Biogen’s Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial

  • MS Drug Therapies
    /
  • MS Research Study and Reports
    /
  • Oral MS Medications
    /
-240 mg of BG-12 Administered Either Twice or Three Times Daily Demonstrated Significant Clinical Effects- WESTON, Mass., Oct 21, 2011…
MS Drug Therapies

October 19, 2011

INVESTIGATIONAL LAQUINIMOD DEMONSTRATES ITS POTENTIAL AS A NEW ORAL TREATMENT FOR RRMS

  • MS Drug Therapies
    /
Wed Oct 19, 2011 2:30am EDT Late-breaking presentation of BRAVO results and additional analyses from ALLEGRO study reinforce novel clinical…
MS Drug Therapies

October 19, 2011

Nutra Pharma Receives Patent for Their Multiple Sclerosis Drug

  • MS Drug Therapies
    /
Nutra Pharma has been issued a patent by the U.S. Patent and Trademark Office that protects their therapy for Multiple…
MS Drug Therapies

October 19, 2011

Multiple Sclerosis Research Roundup October 2011

  • MS Research Study and Reports
    /
Funky Mango has very kindly let us repost her Ovtober round up of multiple sclerosis research!  Funky Mango blogs at http://funkymangosmusings.blogspot.com/ so…
MS Research Study and Reports

Categories

Latest Blog Posts